These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 9158875)

  • 1. Synthesis and biological evaluation of orally active matrix metalloproteinase inhibitors.
    Hirayama R; Yamamoto M; Tsukida T; Matsuo K; Obata Y; Sakamoto F; Ikeda S
    Bioorg Med Chem; 1997 Apr; 5(4):765-78. PubMed ID: 9158875
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevention of progressive joint destruction in adjuvant induced arthritis in rats by a novel matrix metalloproteinase inhibitor, FR217840.
    Ishikawa T; Nishigaki F; Miyata S; Hirayama Y; Minoura K; Imanishi J; Neya M; Mizutani T; Imamura Y; Ohkubo Y; Mutoh S
    Eur J Pharmacol; 2005 Jan; 508(1-3):239-47. PubMed ID: 15680277
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and structure-activity relationship of alpha-sulfonylhydroxamic acids as novel, orally active matrix metalloproteinase inhibitors for the treatment of osteoarthritis.
    Aranapakam V; Grosu GT; Davis JM; Hu B; Ellingboe J; Baker JL; Skotnicki JS; Zask A; DiJoseph JF; Sung A; Sharr MA; Killar LM; Walter T; Jin G; Cowling R
    J Med Chem; 2003 Jun; 46(12):2361-75. PubMed ID: 12773041
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Highly selective and orally active inhibitors of type IV collagenase (MMP-9 and MMP-2): N-sulfonylamino acid derivatives.
    Tamura Y; Watanabe F; Nakatani T; Yasui K; Fuji M; Komurasaki T; Tsuzuki H; Maekawa R; Yoshioka T; Kawada K; Sugita K; Ohtani M
    J Med Chem; 1998 Feb; 41(4):640-9. PubMed ID: 9484512
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure-based design and synthesis of a series of hydroxamic acids with a quaternary-hydroxy group in P1 as inhibitors of matrix metalloproteinases.
    Jacobson IC; Reddy PG; Wasserman ZR; Hardman KD; Covington MB; Arner EC; Copeland RA; Decicco CP; Magolda RL
    Bioorg Med Chem Lett; 1998 Apr; 8(7):837-42. PubMed ID: 9871551
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of stromelysin-1 (MMP-3) by P1'-biphenylylethyl carboxyalkyl dipeptides.
    Esser CK; Bugianesi RL; Caldwell CG; Chapman KT; Durette PL; Girotra NN; Kopka IE; Lanza TJ; Levorse DA; MacCoss M; Owens KA; Ponpipom MM; Simeone JP; Harrison RK; Niedzwiecki L; Becker JW; Marcy AI; Axel MG; Christen AJ; McDonnell J; Moore VL; Olszewski JM; Saphos C; Visco DM; Hagmann WK
    J Med Chem; 1997 Mar; 40(6):1026-40. PubMed ID: 9083493
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The synthesis of novel matrix metalloproteinase inhibitors employing the Ireland-Claisen rearrangement.
    Pratt LM; Beckett RP; Bellamy CL; Corkill DJ; Cossins J; Courtney PF; Davies SJ; Davidson AH; Drummond AH; Helfrich K; Lewis CN; Mangan M; Martin FM; Miller K; Nayee P; Ricketts ML; Thomas W; Todd RS; Whittaker M
    Bioorg Med Chem Lett; 1998 Jun; 8(11):1359-64. PubMed ID: 9871766
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and structure-activity relationship of N-substituted 4-arylsulfonylpiperidine-4-hydroxamic acids as novel, orally active matrix metalloproteinase inhibitors for the treatment of osteoarthritis.
    Aranapakam V; Davis JM; Grosu GT; Baker J; Ellingboe J; Zask A; Levin JI; Sandanayaka VP; Du M; Skotnicki JS; DiJoseph JF; Sung A; Sharr MA; Killar LM; Walter T; Jin G; Cowling R; Tillett J; Zhao W; McDevitt J; Xu ZB
    J Med Chem; 2003 Jun; 46(12):2376-96. PubMed ID: 12773042
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design and synthesis of matrix metalloproteinase inhibitors guided by molecular modeling. Picking the S(1) pocket using conformationally constrained inhibitors.
    Hanessian S; MacKay DB; Moitessier N
    J Med Chem; 2001 Sep; 44(19):3074-82. PubMed ID: 11543676
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chromen-based TNF-alpha converting enzyme (TACE) inhibitors: design, synthesis, and biological evaluation.
    Chun K; Park SK; Kim HM; Choi Y; Kim MH; Park CH; Joe BY; Chun TG; Choi HM; Lee HY; Hong SH; Kim MS; Nam KY; Han G
    Bioorg Med Chem; 2008 Jan; 16(1):530-5. PubMed ID: 17936631
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Beta-aryl-succinic acid hydroxamates as dual inhibitors of matrix metalloproteinases and tumor necrosis factor alpha converting enzyme.
    Kottirsch G; Koch G; Feifel R; Neumann U
    J Med Chem; 2002 May; 45(11):2289-93. PubMed ID: 12014967
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I trial of Marimastat, a novel matrix metalloproteinase inhibitor, administered orally to patients with advanced lung cancer.
    Wojtowicz-Praga S; Torri J; Johnson M; Steen V; Marshall J; Ness E; Dickson R; Sale M; Rasmussen HS; Chiodo TA; Hawkins MJ
    J Clin Oncol; 1998 Jun; 16(6):2150-6. PubMed ID: 9626215
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phenoxyphenyl sulfone N-formylhydroxylamines (retrohydroxamates) as potent, selective, orally bioavailable matrix metalloproteinase inhibitors.
    Wada CK; Holms JH; Curtin ML; Dai Y; Florjancic AS; Garland RB; Guo Y; Heyman HR; Stacey JR; Steinman DH; Albert DH; Bouska JJ; Elmore IN; Goodfellow CL; Marcotte PA; Tapang P; Morgan DW; Michaelides MR; Davidsen SK
    J Med Chem; 2002 Jan; 45(1):219-32. PubMed ID: 11754593
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I trial of a novel matrix metalloproteinase inhibitor batimastat (BB-94) in patients with advanced cancer.
    Wojtowicz-Praga S; Low J; Marshall J; Ness E; Dickson R; Barter J; Sale M; McCann P; Moore J; Cole A; Hawkins MJ
    Invest New Drugs; 1996; 14(2):193-202. PubMed ID: 8913840
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of 3-OH-3-methylpipecolic hydroxamates: potent orally active inhibitors of aggrecanase and MMP-13.
    Noe MC; Natarajan V; Snow SL; Wolf-Gouveia LA; Mitchell PG; Lopresti-Morrow L; Reeves LM; Yocum SA; Otterness I; Bliven MA; Carty TJ; Barberia JT; Sweeney FJ; Liras JL; Vaughn M
    Bioorg Med Chem Lett; 2005 Jul; 15(14):3385-8. PubMed ID: 15953722
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aryl ketones as novel replacements for the C-terminal amide bond of succinyl hydroxamate MMP inhibitors.
    Sheppard GS; Florjancic AS; Giesler JR; Xu L; Guo Y; Davidsen SK; Marcotte PA; Elmore I; Albert DH; Magoc TJ; Bouska JJ; Goodfellow CL; Morgan DW; Summers JB
    Bioorg Med Chem Lett; 1998 Nov; 8(22):3251-6. PubMed ID: 9873712
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of membrane-type 1 matrix metalloproteinase by hydroxamate inhibitors: an examination of the subsite pocket.
    Yamamoto M; Tsujishita H; Hori N; Ohishi Y; Inoue S; Ikeda S; Okada Y
    J Med Chem; 1998 Apr; 41(8):1209-17. PubMed ID: 9548812
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design and synthesis of a series of (2R)-N(4)-hydroxy-2-(3-hydroxybenzyl)-N(1)- [(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]butanediamide derivatives as potent, selective, and orally bioavailable aggrecanase inhibitors.
    Yao W; Wasserman ZR; Chao M; Reddy G; Shi E; Liu RQ; Covington MB; Arner EC; Pratta MA; Tortorella M; Magolda RL; Newton R; Qian M; Ribadeneira MD; Christ D; Wexler RR; Decicco CP
    J Med Chem; 2001 Oct; 44(21):3347-50. PubMed ID: 11585439
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of gamma-lactam hydroxamic acids as selective inhibitors of tumor necrosis factor alpha converting enzyme: design, synthesis, and structure-activity relationships.
    Duan JJ; Chen L; Wasserman ZR; Lu Z; Liu RQ; Covington MB; Qian M; Hardman KD; Magolda RL; Newton RC; Christ DD; Wexler RR; Decicco CP
    J Med Chem; 2002 Nov; 45(23):4954-7. PubMed ID: 12408705
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design strategies for the identification of MMP-13 and Tace inhibitors.
    Skotnicki JS; DiGrandi MJ; Levin JI
    Curr Opin Drug Discov Devel; 2003 Sep; 6(5):742-59. PubMed ID: 14579524
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.